v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04828668 |
Full text link
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : Nov. 17, 2021, 7 p.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : Nov. 17, 2021, 7 p.m. Source : ClinicalTrials.gov |
tpy@n2ymedical.com |
Registration date
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
2021-04-02 |
Recruitment status
Last imported at : Sept. 23, 2022, 4 a.m. Source : ClinicalTrials.gov |
Completed |
Study design
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Crossover |
Masking
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Blind label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
single-center |
Study aim
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Long covid |
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
inclusion criteria: age 18 years of age or older who can provide informed consent. persons who have been diagnosed with covid-19 and now in post-acute recovery phase. persons who are in care with access to primary care for post covid infection or pacs. ability to read and write in the english language and follow study-related procedures. ability to have mail/ study drug delivered to an address and/or p.o. box in the recipient's name. ability to participate in telemedicine visits/communication. if a woman of childbearing age, willing to use a dual method of contraception (barrier and/or hormonal). |
Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
active illicit or non-prescribed drug use. concomitant use of benzodiazepines. concomitant use of an immune suppressant agent, e.g., prednisone. documented history and active treatment for seizure disorder. transaminase elevation. active autoimmune disorder. hepatitis c infection (currently on therapy and/or any transaminitis elevation). hepatitis b infection (currently on therapy and/or any transaminitis elevation). human immune deficiency virus (hiv-1 or hiv-2) infection that is newly diagnosed or untreated. any form of mental impairment that will/could hinder safe participation in the study. pregnancy or breast-feeding. any condition that in the opinion of the investigator would be harmful or detrimental to the participant. |
Number of arms
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Endourage, LLC |
Inclusion age min
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
75 |
Countries
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
United States |
Type of patients
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
Patients recovered from covid |
Severity scale
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
N/A |
Total sample size
Last imported at : Sept. 23, 2022, 4 a.m. Source : ClinicalTrials.gov |
32 |
primary outcome
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
PATIENT GLOBAL IMPRESSION OF CHANGE (PGIC);Reduction in patient reported outcomes measures on the Patient Reported Outcomes Measurement Information System (PROMIS ®) assessment tools. |
Notes
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
Not reported |
Arms
Last imported at : April 6, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
[{"arm_notes": " ", "treatment_id": 567, "treatment_name": "Hemp seed oil", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": " ", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}] |